Phreesia [PHR] vs 10x Genomics [TXG] Detailed Stock Comparison
Phreesia
NYSE
Loading...
10x Genomics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Phreesia wins in 9 metrics, 10x Genomics wins in 8 metrics, with 0 ties. Phreesia appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Phreesia | 10x Genomics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -8.09 | N/A |
| Price-to-Book Ratio | 5.34 | 1.97 | 10x Genomics |
| Debt-to-Equity Ratio | 2.60 | 11.22 | Phreesia |
| PEG Ratio | -40.10 | -10.07 | Phreesia |
| EV/EBITDA | -27.85 | -10.13 | Phreesia |
| Profit Margin (TTM) | -13.94% | -13.13% | 10x Genomics |
| Operating Margin (TTM) | -46.68% | -6.12% | 10x Genomics |
| Return on Equity | -22.67% | -11.30% | 10x Genomics |
| Return on Assets (TTM) | -8.75% | -9.71% | Phreesia |
| Free Cash Flow (TTM) | $8.29M | $-6.73M | Phreesia |
| 1-Year Return | 16.83% | -39.84% | Phreesia |
| Price-to-Sales Ratio (TTM) | 3.41 | 2.35 | 10x Genomics |
| Enterprise Value | $986.85M | $1.16B | 10x Genomics |
| EV/Revenue Ratio | 2.35 | 1.80 | 10x Genomics |
| Gross Profit Margin (TTM) | 69.40% | 68.08% | Phreesia |
| Revenue per Share (TTM) | $7 | $5 | Phreesia |
| Earnings per Share (Diluted) | $-1.02 | $-0.70 | 10x Genomics |
| Beta (Stock Volatility) | 0.74 | 2.03 | Phreesia |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Phreesia vs 10x Genomics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Phreesia | 0.63% | 2.54% | -4.93% | 6.42% | -6.80% | 7.23% |
| 10x Genomics | -3.98% | -6.04% | 0.33% | 42.41% | 1.91% | -13.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Phreesia | 16.83% | 4.53% | -9.48% | 12.54% | 12.54% | 12.54% |
| 10x Genomics | -39.84% | -74.52% | -88.03% | -76.49% | -76.49% | -76.49% |
Performance & Financial Health Analysis: Phreesia vs 10x Genomics
| Metric | PHR | TXG |
|---|---|---|
| Market Information | ||
| Market Cap | $1.43B | $1.51B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 403,230 | 3,254,710 |
| 90 Day Avg. Volume | 422,913 | 3,636,777 |
| Last Close | $27.01 | $12.29 |
| 52 Week Range | $17.07 - $30.53 | $6.78 - $24.76 |
| % from 52W High | -11.53% | -50.36% |
| All-Time High | $81.59 (Feb 08, 2021) | $208.99 (Jun 28, 2021) |
| % from All-Time High | -66.90% | -94.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.46% | 0.13% |
| Quarterly Earnings Growth | 0.15% | 0.10% |
| Financial Health | ||
| Profit Margin (TTM) | -0.14% | -0.13% |
| Operating Margin (TTM) | -0.47% | -0.06% |
| Return on Equity (TTM) | -0.23% | -0.11% |
| Debt to Equity (MRQ) | 2.60 | 11.22 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.51 | $6.25 |
| Cash per Share (MRQ) | $7.48 | $3.61 |
| Operating Cash Flow (TTM) | $32.38M | $18.24M |
| Levered Free Cash Flow (TTM) | $28.64M | $-182,627,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Phreesia vs 10x Genomics
| Metric | PHR | TXG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -8.09 |
| Forward P/E | -40.10 | -10.07 |
| PEG Ratio | -40.10 | -10.07 |
| Price to Sales (TTM) | 3.41 | 2.35 |
| Price to Book (MRQ) | 5.34 | 1.97 |
| Market Capitalization | ||
| Market Capitalization | $1.43B | $1.51B |
| Enterprise Value | $986.85M | $1.16B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.35 | 1.80 |
| Enterprise to EBITDA | -27.85 | -10.13 |
| Risk & Other Metrics | ||
| Beta | 0.74 | 2.03 |
| Book Value per Share (MRQ) | $4.51 | $6.25 |
Financial Statements Comparison: Phreesia vs 10x Genomics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PHR | TXG |
|---|---|---|
| Revenue/Sales | $109.68M | $154.88M |
| Cost of Goods Sold | $33.57M | $49.44M |
| Gross Profit | $76.12M | $105.45M |
| Research & Development | $29.63M | $64.25M |
| Operating Income (EBIT) | $-7.61M | $-48.53M |
| EBITDA | $2.03M | $-32.89M |
| Pre-Tax Income | $-5.38M | $-33.51M |
| Income Tax | $1.01M | $852,000 |
| Net Income (Profit) | $-6.39M | $-34.36M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PHR | TXG |
|---|---|---|
| Cash & Equivalents | $84.22M | $377.06M |
| Total Current Assets | $203.29M | $579.73M |
| Total Current Liabilities | $114.02M | $107.90M |
| Long-Term Debt | $8.80M | $70.63M |
| Total Shareholders Equity | $264.81M | $706.90M |
| Retained Earnings | $-801.50M | $-1.50B |
| Property, Plant & Equipment | $17.24M | $55.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PHR | TXG |
|---|---|---|
| Operating Cash Flow | $15.59M | $35.44M |
| Capital Expenditures | $-2.79M | $-1.89M |
| Free Cash Flow | $9.20M | $32.46M |
| Debt Repayment | $-2.64M | N/A |
| Common Stock Repurchase | $0 | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PHR | TXG |
|---|---|---|
| Shares Short | 2.34M | 14.26M |
| Short Ratio | 4.77 | 3.41 |
| Short % of Float | 0.05% | 0.19% |
| Average Daily Volume (10 Day) | 403,230 | 3,254,710 |
| Average Daily Volume (90 Day) | 422,913 | 3,636,777 |
| Shares Outstanding | 58.73M | 122.29M |
| Float Shares | 56.03M | 109.56M |
| % Held by Insiders | 0.04% | 0.02% |
| % Held by Institutions | 0.97% | 1.06% |
Dividend Analysis & Yield Comparison: Phreesia vs 10x Genomics
| Metric | PHR | TXG |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |